Luxabendazole

Luxabendazole

SCHEMBL1193261

COC(=O)Nc1nc2ccc(OS(=O)(=O)c3ccc(F)cc3)cc2[nH]1.[NaH]

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.66
TUBB P07437 4/20 0.66
TUBA3C P0DPH7 4/20 0.66
TUBA1B P68363 4/20 0.66
TUBA4A P68366 4/20 0.66
TUBB4B P68371 4/20 0.66
TUBB3 Q13509 4/20 0.66
TUBB2A Q13885 4/20 0.66
TUBB8 Q3ZCM7 4/20 0.66
TUBA3E Q6PEY2 4/20 0.66
TUBA1A Q71U36 4/20 0.66
TUBA1C Q9BQE3 4/20 0.66
TUBB6 Q9BUF5 4/20 0.66
TUBB2B Q9BVA1 4/20 0.66
TUBB1 Q9H4B7 4/20 0.66
MET P08581 2/20 0.66
CDK9 P50750 2/20 0.66
KDR P35968 6/20 0.62
MAPK1 P28482 3/20 0.62
ADORA3 P0DMS8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Luxabendazole SCHEMBL321908 0.99 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Luxabendazole SCHEMBL6055930 0.91 TUBB4A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
Luxabendazole SCHEMBL29765623 0.91 TUBB4A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11868259 0.90 TUBB4A (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11868920 0.89 TUBB4A (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5036244 0.89 MET (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11878160 0.88 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11870396 0.88 TUBB4A (0.73) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14300495 0.88 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5033395 0.87 TUBB4A (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893271-B2 Benzimidazole carbamates and (thio) carbamates, and the synthesis and use thereof INTERVET INTERNATIONAL B.V. (NL) 2011-02-22 US disclosed
EP-1913009-B1 NOVEL BENZIMIDAZOLE (THIO) CARBAMATES WITH ANTIPARASITIC ACTIVITY AND THE SYNTHESIS THEREOF INTERVET INT BV (NL) 2010-05-12 EP disclosed
US-20090131369-A1 Novel Benzimidazole(Thio)Carbamates with Antiparasitic Activity and the Synthesis Thereof INTERVET INTERNATIONAL B.V. (NL) 2009-05-21 US disclosed
EP-1913009-A1 NOVEL BENZIMIDAZOLE (THIO) CARBAMATES WITH ANTIPARASITIC ACTIVITY AND THE SYNTHESIS THEREOF Intervet International BV (NL) 2008-04-23 EP disclosed
WO-2007014846-A1 NOVEL BENZIMIDAZOLE (THIO) CARBAMATES WITH ANTIPARASITIC ACTIVITY AND THE SYNTHESIS THEREOF INTERVET INTERNATIONAL B.V. (NL) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131369-A1 Novel Benzimidazole(Thio)Carbamates with Antiparasitic Activity and the Synthesis Thereof CYP2C8, CYP3A7, CYP8B1 TUBB4A 558/4885TUBB 280/4885TUBA3C 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.